Pharma Stocks Are Bleeding. But These 2 Look Like Bargains.

  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 60 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 27%
  • Publisher: 97%

Österreich Nachrichten Nachrichten

Österreich Neuesten Nachrichten,Österreich Schlagzeilen

With many drugmakers struggling, it could be a good time to buy.

Investors have mostly had one reaction to drugmakers’ earnings this quarter: Slam that big red “sell” button, and slam it hard.

The latest no good, very bad earnings season started with Johnson & Johnson , which on Oct. 17 raised its full-year guidance and announced third quarter earnings that beat Wall Street estimates. Shares fell 0.9% anyhow, eventually sliding to a 52-week low on October 27. The selloffs came at a low ebb in investor sentiment around big pharma, with the exception of the two companies behind the new anti-obesity drugs, Eli Lilly and Novo Nordisk . While Lilly’s shares are up 55.8% this year, and Novo’s are up 45.5%, the rest of the sector is trailing the market. In a year when the S&P 500 is up 13.5%, Pfizer is down 39%, Bristol Myers down 26.7%, Merck down 6.6%, and Johnson & Johnson down14.3%.

Despite all those headwinds, shares of a few of the drugmakers still seem cheap, especially after the recent selloffs. One is Merck. “We see MRK’s diversified pipeline/portfolio…as being increasingly well-equipped with commercial opportunities with the potential to generate sustained growth over the intermediate and longer term,” Goldman Sachs analyst Chris Shibutani wrote in an October 27 note. Shibutani has a Buy rating and a $131 target price on the stock.

Wir haben diese Nachrichten zusammengefasst, damit Sie sie schnell lesen können. Wenn Sie sich für die Nachrichten interessieren, können Sie den vollständigen Text hier lesen. Weiterlesen:

 /  🏆 3. in AT
 

Vielen Dank für Ihren Kommentar.Ihr Kommentar wird nach Prüfung veröffentlicht.

Österreich Neuesten Nachrichten, Österreich Schlagzeilen

Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.

Stocks vs. Gold: Where to Place Your November Bets for Maximum Gains?Market Overview Analysis by Investing.com (Ismael De La Cruz) covering: XAU/USD, S&P 500, iShares Core S&P 500 ETF, SPDR® S&P 500. Read Investing.com (Ismael De La Cruz)'s latest article on Investing.com
Herkunft: Investingcom - 🏆 450. / 53 Weiterlesen »

12 Warren Buffett Style Dividend Stocks With A Margin Of SafetyI am the editor of three Forbes investment newsletters: Forbes Dividend Investor, Forbes Billionaire Investor and covered call writing advisory service, Forbes Premium Income Report. Prior to joining Forbes in 2001, I was a producer and reporter at CNN Financial News, focusing on stories about entrepreneurship.
Herkunft: Forbes - 🏆 394. / 53 Weiterlesen »

Stocks enjoy best week in a yearA perfect combination of data, Fedspeak and earnings are putting wind in Wall Street's sails.
Herkunft: axios - 🏆 302. / 63 Weiterlesen »